Table of Contents
Metal-Based Drugs
Volume 4 (1997), Issue 6, Pages 333-338
http://dx.doi.org/10.1155/MBD.1997.333

Rh2(CF3CONH)4: The First Biological Assays of a Rhodium (II) Amidate

1Institute of Chemistry, University of São Paulo, Av. Lineu Prestes 748, São Paulo 05508-900, Brazil
2Institute of Biomedical Sciences - I, University of São Paulo, Av. Lineu Prestes 1524, São Paulo 05508-900, Brazil
3Institute of Chemistry, Federal University of Goiás, Campus II, P.O. Box 131, Goiânia 74001-970, Brazil

Received 20 October 1997; Accepted 3 December 1997

Copyright © 1997 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The rhodium (II) complexes Rh2(tfa)4.2(tfac) and Rh2(tfacam)4 (tfacam = CF3CONH-,tfa = CF3COO-,tfac = CF3CONH2) were synthesized and characterized by microanalysis and electronic and vibrational spectroscopies. Rh2(tfacam)4 was tested both in vitro (U937 and K562 human leukemia cells and Ehrlich ascitic tumor cells) and in vivo for cytostatic activity and lethal dose determination, respectively. This is the first rhodium tetra-amidate to have its biological activity evaluated. The LD50 value for Rh2(tfacam)4 is of the same order as that of cisplatin, and it was verified that the rhodium complex usually needs lower doses than cisplatin to promote the same inhibitory effects.